LPTX Stock Risk & Deep Value Analysis
LPTX
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on LPTX
We analyzed LPTX using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran LPTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
Get notified when LPTX moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈LPTX Performance Overview3yr weekly
Unlock LPTX Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
LPTX Quality Rating
LPTX Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
About LPTX (LPTX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$116.14M
LPTX Deep Value Analysis
LPTX Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
LPTX Red Flags & Warning Signs
- ⚠
Negative or inconclusive DKN-01 clinical trial results
- ⚠
Further significant dilutive financing rounds impacting shareholder value
- ⚠
Competitor drug approvals in gastric/GEJ cancer
Unlock LPTX Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
LPTX Financial Health Metrics
Market Cap
$116.14M
P/E Ratio
-5.12
Profit Margin
-2705.80%
Debt-to-Equity
0.12
Beta (Volatility)
1.70
Earnings Per Share
$-1.59
LPTX Competitive Moat Analysis
Moat Rating
None
Moat Trend
Stable
Moat Sources
1 Identified
The potential moat relies entirely on the successful clinical development and eventual regulatory approval of DKN-01, establishing a strong patent-protected therapeutic. Until then, there is no durable competitive advantage, and the drug's efficacy and safety must outperform existing or emerging treatments.
LPTX Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
LPTX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Estimated Q4 2025/Q1 2026 Earnings Report (May 18, 2026)
- •Updates on DKN-01 Phase 2 clinical trial enrollment and progress
Medium-Term (6-18 months)
- •Potential interim or full Phase 2 DKN-01 clinical trial data readout (H2 2026/H1 2027)
- •Possible strategic partnership or licensing deal for DKN-01 based on positive data
Long-Term (18+ months)
- •DKN-01 regulatory approval and commercialization in gastric/GEJ cancer
- •Pipeline expansion with additional oncology assets
Catalysts & Growth Drivers
Sign up free to see growth catalysts
LPTX Bull Case: What Could Go Right
- ✓
Positive Phase 2 DKN-01 clinical data (efficacy and safety)
- ✓
Announcement of a strategic partnership or licensing agreement
- ✓
Significant insider buying activity
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for LPTX (LPTX)?
As of April 17, 2026, LPTX has a DVR Score of 2.7 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of LPTX?
LPTX's market capitalization is approximately $116.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does LPTX use?
LPTX is the ticker symbol for LPTX. The company trades on the NCM.
What is the risk level for LPTX stock?
Our analysis rates LPTX's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of LPTX?
LPTX currently has a price-to-earnings (P/E) ratio of -5.1. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is LPTX's revenue growing?
LPTX has reported revenue growth of 12.0%. The company is showing strong top-line momentum.
Is LPTX stock profitable?
LPTX has a profit margin of -2705.8%. The company is currently unprofitable.
How often is the LPTX DVR analysis updated?
Our AI-powered analysis of LPTX is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 17, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.